- Home
- LUCD vs IOBT Comparison
LUCD vs IOBT Comparison
Compare LUCD & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- IOBT
- Stock Information
- Founded
- LUCD 2018
- IOBT 2014
- Country
- LUCD United States
- IOBT Denmark
- Employees
- LUCD 70
- IOBT N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- IOBT Health Care
- Exchange
- LUCD Nasdaq
- IOBT Nasdaq
- Market Cap
- LUCD 108.0M
- IOBT 114.6M
- IPO Year
- LUCD 2021
- IOBT 2021
- Fundamental
- Price
- LUCD $1.07
- IOBT $1.75
- Analyst Decision
- LUCD Strong Buy
- IOBT Strong Buy
- Analyst Count
- LUCD 5
- IOBT 2
- Target Price
- LUCD $3.65
- IOBT $8.00
- AVG Volume (30 Days)
- LUCD 1.6M
- IOBT 1.2M
- Earning Date
- LUCD 11-12-2025
- IOBT 11-11-2025
- Dividend Yield
- LUCD N/A
- IOBT N/A
- EPS Growth
- LUCD N/A
- IOBT N/A
- EPS
- LUCD N/A
- IOBT N/A
- Revenue
- LUCD $4,360,000.00
- IOBT N/A
- Revenue This Year
- LUCD $22.80
- IOBT N/A
- Revenue Next Year
- LUCD $221.19
- IOBT N/A
- P/E Ratio
- LUCD N/A
- IOBT N/A
- Revenue Growth
- LUCD 14.74
- IOBT N/A
- 52 Week Low
- LUCD $0.73
- IOBT $0.66
- 52 Week High
- LUCD $1.80
- IOBT $2.79
- Technical
- Relative Strength Index (RSI)
- LUCD 50.26
- IOBT 48.50
- Support Level
- LUCD N/A
- IOBT $1.71
- Resistance Level
- LUCD $1.09
- IOBT $2.08
- Average True Range (ATR)
- LUCD 0.09
- IOBT 0.15
- MACD
- LUCD -0.06
- IOBT 0.00
- Stochastic Oscillator
- LUCD 69.53
- IOBT 40.00
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.